In this study, another immunological adjuvant QS-21 was tested but no patient developed an immunization with this strategy.88 In phase 2 clinical trial including 50 patients with melanoma after complete resection and at high risk of relapse, surprisingly, Chapman et al. found that a dose of Bec2 < 2.5 mg (2.5, 25, and 250 μg) was more immunogenic in melanoma than all the other doses (5 and 10 mg).71 Here, KCNH4 is linked to melanoma.